INTERIM REPORT Q1 2019
Summary of Q1 “The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.”Financial overview January 1 – March 31, 2019 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 122.2 M (loss: 62.0) · Loss per share, before and after dilution, was SEK 2.57 (loss: 1.56) · On March 31 cash and cash equivalents amounted to SEK 747.5 M (664.9) Significant events during the period January 1 – March 31, 2019 · In January, Oncopeptides completed a directed share issue of SEK 546.2 M (USD 60.0 M) before issue costs ·